Patent ID: 11911445
Assignee: GILA THERAPEUTICS, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A | IPC A

Claim 7:
8. The pharmaceutical composition of claim 1, further comprising one or more active pharmaceutical ingredients selected from the group consisting of Glucagon-like peptide-1 (GLP-1), oxyntomodulin (OXM), and cholecystokinin acetyl-CoA carboxylase-(ACC) inhibitor, a diacylglycerol O-acyltransferase 1 (DGAT-1) inhibitor, monoacylglycerol O-acyltransferase inhibitors, a phosphodiesterase (PDE)-10 inhibitor, an AMP-activated protein kinase (AMPK) activator, a sulfonylurea, a meglitinide, an α-amylase inhibitor, an α-glucoside hydrolase inhibitor, an α-glucosidase inhibitor, a peroxisome proliferator-activated receptor gamma (PPARγ) agonist, a PPAR α/γ agonist, a biguanide, a GLP-1 modulator, a GLP-1 receptor agonist, a protein tyrosine phosphatase-IB (PTP-IB) inhibitor, a sirtuin-1 (SIRT-1) activator, a dipeptidyl peptidase IV (DPP-IV) inhibitor, an insulin secreatagogue, a fatty acid oxidation inhibitor, an A2 antagonist, a c-jun amino-terminal kinase (JNK) inhibitor, glucokinase activators (GKa), insulin, an insulin mimetic, a glycogen phosphorylase inhibitor, a vasoactive intestinal peptide receptor 2 (VPAC2) receptor agonist, a sodium glucose co-transporter 2 (SGLT2) inhibitor, a glucagon receptor modulator, a G protein-coupled receptor 19 (GPCR19) modulator, a fibroblast growth factor 21 (FGF21) derivative or analog, a free fatty acid receptor 1 (FFA1) agonist, a free fatty acid receptor 4 (FFA4) modulators, a high affinity nicotinic acid receptor (HM74A) activator, a sodium-D-glucose cotransporter (SGLTI) inhibitor, an inhibitor or modulator of a carnitine palmitoyl transferase enzyme, a fructose 1,6-diphosphatase inhibitor, an aldose reductase inhibitor, a mineralocorticoid receptor inhibitor, a target of rapamycin kinase multiprotein complex (TORC2) inhibitor, a C-C chemokine receptor type 2 (CCR2) and/or a C-C chemokine receptor type 5 (CCR5) inhibitor, a protein kinase C (PKC) inhibitor, a fatty acid synthetase inhibitor, a serine palmitoyl transferase inhibitor, a G protein-coupled receptor 81 (GPR81) modulator, a G protein-coupled receptor 39 (GPR39) modulator, a G protein-coupled receptor 43 (GPR43) modulator, a G protein-coupled receptor 41 (GPR41) modulator, a G protein-coupled receptor 105 (GPR105) modulator, voltage-gated potassium channel (Kv1.3), retinal binding protein 4, glucocorticoid receptor, a somatostatin receptor, an inhibitor or modulator of pyruvate dehydrogenase kinase isoform 2 (PDHK2) or pyruvate dehydrogenase kinase isoform 4 (PDHK4), an inhibitor of mitogen-activated protein kinase kinase kinase kinase 4 (MAP4K4), an interleukin 1 modulator, a 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase inhibitor, a squalene synthetase inhibitor, a fibrate, a bile acid sequestrant, an acyl-CoA cholesterol acyltransferase (ACAT) inhibitor, a microsomal triglyceride transfer protein (MTP) inhibitor, a lipooxygenase inhibitor, a cholesterol absorption inhibitor, a proprotein convertase subtilisin/kexin type 9 (PCSK9) modulator, a cholesteryl ester transfer protein inhibitor, a modulator of retinoid x receptor α (RXRα), a gastric inhibitory polypeptide receptor (GIP) agonist, enterostatin or an enterostatin analog, amylin or an amylin receptor agonist, a ghrelin modulator, leptin or a leptin receptor agonist, a pancreatic polypeptide (PP), calcitonin, neuropeptide Y (NPY), human growth hormone, prolactin, oxytocin, bovine growth hormone, porcine growth hormone, ghrelin, or glucagon.